Dateline: November 14, 2025 — Dublin, Ireland
Trinity Biotech has announced a strategic collaboration with a leading bioinformatics partner to advance the analytical depth and development of EpiCapture, its PCR-based epigenetic liquid biopsy test designed to monitor the risk of prostate cancer progressing into more aggressive disease. The partnership aims to apply sophisticated data-analysis tools to late-stage clinical-trial datasets, strengthening the test’s performance profile and supporting its path toward regulatory submission and commercialization.
Science Significance
This collaboration enhances the scientific rigor behind EpiCapture, which identifies DNA methylation patterns linked to high-grade prostate cancer. By integrating advanced bioinformatics, Trinity Biotech seeks to improve signal fidelity, refine biomarker interpretation and strengthen clinical validity. The test already demonstrates compelling potential: in a published clinical study, EpiCapture successfully predicted all high-grade cancers when combined with standard PSA testing, underscoring its utility in improving risk assessment. These advances position EpiCapture at the forefront of epigenetic diagnostics, where molecular precision increasingly informs cancer monitoring and personalized clinical decisions.
Regulatory Significance
EpiCapture’s progress toward regulatory approval is supported by this data-analytics collaboration, which provides a stronger evidence base for accuracy, clinical utility and reproducibility—key criteria in the IVD regulatory pathway. Trinity Biotech will leverage its New York State–certified reference laboratory, ensuring compliant data generation and readiness for regulatory dossier assembly. This partnership therefore enhances the company’s ability to meet regulatory expectations for analytical validation, clinical validation and manufacturing quality, paving the way for a well-supported submission once late-stage development milestones are complete.
Business Significance
Advertisement
The collaboration represents a strategic expansion of Trinity Biotech’s diagnostics portfolio, strengthening its presence in the high-growth oncology diagnostics market. As a commercial-stage biotechnology company with a footprint in human diagnostics, diabetes management and wearable biosensors, Trinity is diversifying through innovation in molecular tests with strong unmet-need profiles. EpiCapture’s non-invasive nature aligns with healthcare demand for tests that reduce procedural burden and cost. With prostate cancer diagnostics representing a multi-billion-dollar annual market, the successful advancement of EpiCapture could materially enhance the company’s revenue potential and competitive standing.
Patients’ Significance
Prostate cancer is the most common non-skin cancer in U.S. men, and its slow and variable progression often leads to repeated invasive biopsies that carry risks such as bleeding, infection and urinary complications. A reliable, non-invasive epigenetic test could markedly reduce patient burden and improve monitoring accuracy. By detecting methylation signals associated with aggressive disease, EpiCapture offers a means to identify risk earlier, minimize unnecessary procedures and support better-informed treatment choices. This aligns directly with patient-centered cancer-care models emphasizing comfort, safety and precision.
Policy Significance
The collaboration reflects broader health-policy priorities supporting non-invasive diagnostics, early cancer detection and data-driven healthcare. As cancer-care systems seek to reduce unnecessary interventions while improving outcome prediction, tests like EpiCapture align with policy goals around cost efficiency, risk stratification and technology-enabled precision oncology. Furthermore, by expanding molecular diagnostic capability through advanced bioinformatics, the initiative supports ongoing policy emphasis on innovation in regulated diagnostics, strengthening the ecosystem that governs clinical validity, laboratory quality and equitable access to modern cancer-monitoring tools.
Trinity Biotech’s partnership to advance epigenetic analysis for EpiCapture marks a significant step toward commercializing a next-generation prostate-cancer monitoring tool. By combining molecular diagnostics expertise with advanced bioinformatics, the company is reinforcing the scientific, regulatory and clinical foundations of a test designed to fill a substantial unmet need. As development progresses toward regulatory submission, EpiCapture is positioned to become an important addition to precision oncology, offering patients and clinicians a safer, more accurate method to monitor prostate-cancer progression.
Source: Trinity Biotech plc press release
